You are here: Industry Insights > ASCO

News List

ASCO: Pfizer’s dacomitinib bests Iressa in NSCLC overall survival showdown fiercebiotech
June 11, 2018
A phase 3 trial has linked Pfizer’s dacomitinib to better overall survival (OS) than Iressa in nonsmall cell lung cancer (NSCLC).
Janssen debuts promising new cancer data at ASCO pharmafile
June 07, 2018
Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 and 3 data on two of its candidates
Roche's breast, lung cancer offerings fail to impress at ASCO pharmafile
June 07, 2018
Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data which demonstrated only mediocre efficacy for two of its therapies for breast and lung cancer.
AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer pharmafile
June 07, 2018
In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza (olaparib) in combination with J&J’s standard-of-care drug Zytiga (abiraterone) in the tre
AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline worldpharmanews
June 05, 2018
AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer worldpharmanews
June 05, 2018
Novartis will present data from across its oncology portfolio at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 1-5 in Chicago
ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it? fiercepharma
June 04, 2018
Novartis rolled out positive first-line metastatic Kisqali results at annual ASCO meeting in Chicago.
Biotheranostics Announces Presentation of Key Data for CancerTYPE ID® and Breast Cancer Index™ at ASCO Annual Meeting in Chicago b3cnewswire.
June 04, 2018
heraBiotnostics, Inc. announces new data from studies for both of its proprietary molecular diagnostic tests, CancerTYPE ID and Breast Cancer Index (BCI) to be presented on Saturday,
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer worldpharmanews
May 23, 2018
Novartis will present data from across its oncology portfolio at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 1-5 in Chicago; and the 23rd Annual Congress of the European Hematology Association (EHA)
Shuwen Debuts it's CODAR-ARMS PCR Liquid Biopsy Technology at ASCO 2018 b3cnewswire
May 23, 2018
Shuwen Biotech, a leading provider of innovative diagnostic products and medical diagnostic services, announced that studies based on its proprietary high-sensitivity CODAR-ARMS...

Previous page 1 2 3 4 Next page